Official UK procurement notice
Tender for the Operating Lease of Biological Atomic Force Microscopy (bioAFM)
Authority: Swansea University (Education)
What is being bought
Published requirement descriptionThe Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6 million GBP project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is aimed at developing new therapeutics for the treatment of ovarian cancer.
A key output of the CEAT project is to establish a developmental pipeline for bioAFM applications in clinically acceptable in vitro and ex-vivo disease models, providing molecular, cellular and tissue level morphological, topographical and biomechanical information to support epigenomic investigations and the development of advanced therapeutics. As part of this requirement we have identified the need to loan specific bioAFM advanced technology from a reputable, commercial supplier, providing hybrid instrumentation compatible with current bioAFM facilities within SUMS
CPV: Financial leasing services · Microscopes
The lotProcurement structure
single lot · no lot value publishedLot #1He Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a…Cancelled
he Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6million GBP project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is aimed at developing new therapeutics for the treatment of ovarian cancer.
A key output of the CEAT project is to establish a developmental pipeline for bioAFM applications in clinically acceptable in vitro and ex-vivo disease models, providing molecular, cellular and tissue level morphological, topographical and biomechanical information to support epigenomic investigations and the development of advanced therapeutics. As part of this requirement we have identified the need to loan specific bioAFM advanced technology from a reputable, commercial supplier, providing hybrid instrumentation compatible with current bioAFM facilities within SUMS
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
- Price
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Open procedure
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Cancelled
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 8 Mar 2021, 14:48 GMT
- Last source update
- 8 Mar 2021, 14:48 GMT
- Authority reference
SU135(20)- FTS notice number
2021/S 000-004611- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-029974Find a Tender
Publisher note: The funding for this equipment is on the basis of an Operating Lease for the duration of the project (WA Ref:108879)
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast1 further award records carry no date or value.
Contracting authority & participating public bodies
2 public bodies on the noticeOther public bodies
- European UnionFunder
Dispute resolution & review bodies
- High CourtReview body
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.